A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies (NCT06507306)
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to learn if KQB198 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are: * What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs? * Does KQB198 alone or in combination with other anti-cancer drugs decrease the size of the tumor? * What happens to KQB198 in the body? Participants will: * Take KQB198 daily, alone or in combination with another anti-cancer drug * Visit the clinic about 8 times in the first 8 weeks, and then once every 4 weeks after that
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (7 items) and avoid the listed exclusions (5 items).
Location: Sarah Cannon Research Institute at HealthONE — Denver, Colorado
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Prior therapy with a similar mechanism of action to KQB198
- History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of study treatment or result in inability to swallow
- History of interstitial lung disease
- Cardiac abnormalities
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (26 Sites)
- Sarah Cannon Research Institute at HealthONE — Denver, Colorado
- Sarah Cannon Research Institute at Florida Cancer Specialists - Lake Nona - — Orlando, Florida
- Florida Cancer Specialists - Sarasota — Sarasota, Florida
- Henry Ford Health System — Detroit, Michigan
- David H. Koch Center for Cancer Center at Memorial Sloan Kettering Cancer Center — Long Island City, New York
- The Lindner Center for Research and Education at The Christ Hospital — Cincinnati, Ohio
- Sarah Cannon and HCA Research Institute — Nashville, Tennessee
- New Experimental Therapeutics of San Antonio - NEXT Oncology — San Antonio, Texas
- New Experimental Therapeutics of Virginia - NEXT Oncology — Fairfax, Virginia
- Institut Paoli-Calmettes — Marseille, Bouches-du-Rhône
- Institut de Cancerologie de l'Ouest - site St-Herblain — Saint-Herblain, Loire-Atlantique
- CHU Bordeaux - Hopital Saint-Andre — Bordeaux, Nouvelle-Aquitane
- IUCT-Oncopole — Toulouse, Occitaine
- CHU de Nantes - Hopital Nord Laennec — Nantes, Pays de la Loire Region
- Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore — Rome, Lazio
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" — Naples,
- Hospital Universitari Quiron Dexeus Barcelona — Barcelona, Catalonia
- Hospital Universitario Vall d'Hebron — Barcelona, Catalonia
- New Experimental Therapeutics (NEXT) Oncology Barcelona — Barcelona,
- South Texas Accelerated Research Therapeutics (START) Barcelona- HM Nou Delfos — Barcelona,
- Hospital Universitario Ramon y Cajal — Madrid,
- South Texas Accelerated Research Therapeutics (START) Madrid - CIOCC — Madrid,
- New Experimental Therapeutics (NEXT) Oncology Madrid - Hospital Quironsalud Madrid — Madrid,
- South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz — Madrid,
- Hospital Quirónsalud Málaga — Málaga,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.